Fran Gregory, PharmD, vice president of emerging therapies at Cardinal Health, discusses how specialty pharmacists manage inventory, storage, and handling of biosimilars.
With the volume of new biosimilars coming to the market, there will be many challenges to specialty pharmacies will need to consider when handling these drugs that are unique from generic drugs, says Fran Gregory, PharmD, vice president of emerging therapies at Cardinal Health.
Transcript
What strategies can specialty pharmacies implement to effectively manage the handling of biosimilars, which may have unique requirements compared with traditional generic medications?
Yes, the inventory management is something I have heard a lot of concern about with biosimilars from specialty pharmacies in particular, and retail pharmacies when we think about the insulins coming to market and the vast number of biosimilars that will come to market for 1 reference product. If in your pharmacy you have 20 boxes of Humira on your shelf, you're now going to have 20 × 10 different rows of Humira biosimilars on your shelf; that gets overwhelming to think about from a sheer capacity and volume and storage requirements. How many more refrigerators am I going to need to buy very tactical things that manufacturers might not be thinking about, or the FDA might not have been thinking about when we created these approval pathways and designations? Specialty pharmacies are hopefully preparing and planning for the launch of these multiple biosimilars.
Because it is a different world that we're coming into and the way that formularies will choose their biosimilar of choice, they will be challenged to maintain significantly larger volume of inventory more likely than they may have previously. I think the other piece of that is having a really good in-time inventory supplier. So, making sure that you have a supplier that can ship your medications overnight when you need them so your patients aren't waiting; so that you don't have any out-of-stock medications, and just making sure that you really manage your inventory, maybe much more closely than you would maybe think you would have to bet the reference product.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
EHA 2024: Rituximab Biosimilars Improve Quality of Life, Infusion-Related Reactions
June 27th 2024Two posters presented at the European Hematology Association’s annual meeting (EHA 2024) evaluated how rituximab biosimilars impact quality of life and infusion-related reactions in patients with lymphatic cancers.
Biosimilar Adoption in the UK: Patient and Consultant Views on Safety and Switching
June 26th 2024Lack of knowledge and confidence in biosimilars continues despite growing education efforts, impacting provider willingness to prescribe biosimilar medicines and patient perceptions about their treatment and switching to a biosimilar.